A liquid chromatography-tandem mass spectrometry method was developed and validated for the simultaneous determination of simvastatin (SV) and simvastatin acid (SVA) in human plasma. To improve assay sensitivity and achieve simultaneous analysis, SVA monitored in (−)ESI (electrospray ionization) mode within the first 4.5 min and SV thereafter in (+)ESI mode. The separation of all compounds was achieved in about 6.2 min using a C 18 reverse-phase fused-core ® column (Ascentis ® Express C 18 ) and a mobile phase, which was composed of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 3.8 with glacial acetic acid-acetonitrile (25:75, v/v), in isocratic mode at a flow rate of 0.500 mL/min. Additionally, a solid-phase extraction step was performed to reduce any ion-suppression and/or enhancement effects. The developed method was linear in the concentration range of 0.100-74.626 ng/mL for SV, and 0.100-48.971 ng/mL for SVA, with correlation coefficient greater than 0.99 for both analytes. The method has shown tremendous reproducibility, with intra-and inter-day precision <7.6%, and intra-and interday accuracy within ±10.9% of nominal values, for the both analytes. The method was successfully applied to characterize the pharmacokinetic profiles of SV and SVA following an oral administration of 40 mg SV tablet to healthy human volunteers.
Introduction
Simvastatin (SV), a methylated analog of lovastatin, has been most frequently prescribed throughout the world for the treatment of hypercholesterolaemia, a major risk factor for developing atherosclerosis (1) . Following oral administration, this lipophilic lactone pro-drug gets absorbed from the gastrointestinal tract (∼60%) and in the liver gets hydrolyzed to its active β-hydroxy acid form, simvastatin acid (SVA), which serves as a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, an essential enzyme involved in the in vivo cholesterol biosynthesis. Inhibition of this microsomal enzyme results in large reduction of plasma cholesterol levels and thereby dramatically reduces morbidity and mortality in patients with established cardiovascular disease (2) . SV and SVA are extensively bound (>95%) to plasma proteins, particularly to albumin, and has terminal half-life of ∼3 and 1.9 h, respectively (3, 4) . The cytochrome P450 3A (CYP3A4) family is involved in the metabolism of SV. The absolute bioavailability of SVA is only 5% as the prodrug, SV, gets extensively metabolized on first pass through the liver, a primary site of action. Three other metabolites have also been isolated, which are also active inhibitors of HMG-CoA reductase. SV is excreted predominantly in the faeces via the bile as metabolites, with 10-15% being recovered in the urine, mainly in inactive forms (5-7).
Previous publications have described several methods for determination of SV or SV along with its metabolite in plasma, including highperformance liquid chromatography (HPLC) coupled with ultraviolet (UV) (8, 9) or fluorescence detection (10) , gas chromatography-mass spectrometry (GC-MS) (11, 12) , liquid chromatography-mass spectrometry (LC-MS) (13) and liquid chromatography-tandem mass spectrometry (LC-MS-MS) (14) (15) (16) (17) (18) (19) (20) (21) . The methods with UV or fluorescence detection, GC-MS and LC-MS were proved to be time consuming and have drawbacks like higher limit of quantification, large plasma sample for processing, tedious sample clean up procedure and/or longer analytical run time. The details of published LC-MS-MS methodologies are summarized in Table I . Patel et al. (20) have discussed the limitations of the reported methods in detail and established an LC-MS-MS method for simultaneous determination of SV and SVA. However, this method utilized higher plasma aliquot volume (500 µL) and employed a tedious and time-consuming liquidliquid extraction (LLE) process for the extraction of analytes.
In vivo conversion of lactone form to open-acid form and lactonization of acid form have been suggested to be catalyzed by esterases ( paraoxonases) enzyme and uridine diphosphate (UDP)-glucuronosyltransferase (UGTs), respectively (22) . Also, it is reported that apart from the enzymes in plasma, changing plasma pH that increases upon storage may results in degradation of drug and drug metabolites after samples have been collected and during sample processing (23) . The enzymes in plasma and changing pH value of the plasma could significantly affect the interconversion and stability of SV, an example of atypical class, and its metabolite, SVA. This interconversion and instability occur in the samples during storage, stages of sample preparation and detection and seriously impact the accuracy of results during conduct of pharmacokinetic studies (14, 15) . Studies in our laboratory showed that plasma samples spiked with SV only shows a degradation of about 18% when exposed to one freeze-thaw cycle (frozen at −50°C, thawed in ice-cold water bath). However, this fact had not been stated in the previously published articles.
In this research, we report a stability indicating, selective and precise method for the simultaneous determination of SV and SVA in human plasma by LC-MS-MS with negative-positive polarity switching. The test results indicated that the interconversion between SV and SVA was minimized significantly. In addition, the proposed SPE procedure was simple, efficient and easy to automate. This method was fully validated according to the guidelines set by USFDA (24) and successfully applied to characterize the clinical pharmacokinetics of SV and its metabolite in humans following a single oral administration of 40 mg SV tablets.
Experimental

Chemicals and materials
Working standards of SV (99.4%) and SVA (98.7%) were procured from USP and TLC Pharma Chem., Canada, respectively, whereas their respective deuterium labeled, -D6, analog (SV-D6 (98.0%) and SVA-D6 (98.0%)) were purchased from TRC Canada. Ammonium acetate (≥99.9%), acetonitrile (≥99.9%) and methanol (≥99.9%) of LC-MS grade were obtained from FLUKA (Sigma-Aldrich, Steinheim, USA). Analytical-grade formic acid (88.0%) and glacial acetic acid (99.8%) were purchased from Fisher Scientific (Mumbai, India). Oasis ® HLB (30 mg, 1 cc) and solid-phase extraction (SPE) disposable cartridges were obtained from Waters (Milford, MA, USA). All aqueous solutions and buffers were prepared using water that was purified using Milli-Q ® Gradient A10 ® (Millipore, Molscheim Cedex, France). Different individual lots of human plasma, used to prepare calibration standards and quality control (QC) samples, were obtained from Yash Laboratory (Mumbai, India).
LC-MS-MS instrumentation and operating conditions
The LC-MS-MS system consisted of Shimadzu scientific instruments (Shimadzu Corporation; Kyoto, Japan), two LC-20AD pumps, a cooling autosampler (SIL 20AC), a column oven of temperature control (CTO-20AC) and a CBM 20 A controller. The HPLC was coupled to an API-4000 triple-quadrupole mass spectrometer (MDS-Sciex ® ;
Concord, Canada) equipped with an ESI ionization source. Separation of SV, SVA and their corresponding synthetic D6-ISTDs was accomplished within 6.20 min using a Ascentis ® Express C18 (75 × 4.60 mm, 2.7 µm; Supelco, Bellefonte, PA, USA) column and a mobile phase consisted of a mixture of 2 ± 0.05 mM ammonium acetate in water titrated to pH 3.8 ± 0.2 using glacial acetic acid and acetonitrile in the ratio of 25:75, v/v. The flow rate of the mobile phase was set at 0.500 mL/min. An injection volume of 25 µL was used for each analysis. The column and autosampler temperature were maintained at 35 and 5°C, respectively. The mass spectrometer was operated in (−)ESI mode for the first 4.5 min and switched to (+)ESI mode thereafter to improve assay sensitivity. Quantitation was performed by multiple reaction monitoring (MRM) mode of precursor-product ion transitions at m/z 436.3 → 285.2 for SV, m/z 442.5 → 285.2 for SV-D6, m/z 435.3 → 319.2 for SVA and m/z 441.5 → 319.1 for SVA-D6, with dwell time set at 150 ms per transition. Nitrogen was used as the nebulizer, auxiliary, collision and curtain gases. The ESI optimized source parameters were set as follows: collision-activated dissociation (CAD) gas, 6; curtain gas (CUR), 15; gas 1 (nebulizer gas), 50; gas 2 (heater gas), 55; source temperature, 450°C; and turbo ionspray (IS) voltage, −4,500 V in (−) ESI and 5,500 V in (+)ESI. The (−)ESI optimized compound parameters were set as follows: declustering potential (DP), −75 V; entrance potential (EP), −10 V; collision energy (CE), −24 V and collision cell exit potential (CXP), −8 V. Similarly, the (+)ESI optimized compound parameters were set as follows: DP, 38 V; EP, 10 V; CE, 21 V and CXP, 8 V.
Calibration curves were constructed by calculating the analyte to internal standard (ISTD) peak area ratio (y) against analyte concentrations (x). Data acquisition and processing were performed using Analyst version 1.4.1 software (MDS-Sciex ® , Canada).
Preparation of stock and working solutions, calibration standards and QC samples
The calibration standards and QC samples were prepared from two separate sets of stock solutions in parallel. Stock solution of SV and SV-D6 were prepared individually by dissolving the accurately weighed reference standards in acetonitrile to obtain a final concentration of 1,000 µg/mL. Similarly, stock solution of SVA and SVA-D6 were prepared individually by dissolving the accurately weighed reference standards in the acetonitrile-water (50:50, v/v) mixture to obtain a final concentration of 1,000 µg/mL. The prepared stock solutions were stored at −20°C and protected from light until use.
Two sets of working solutions were prepared by serial dilution of stock solutions in methanol-water (50:50, v/v) for the preparation of calibration standards. One set contained SV and another set contained SVA. Calibrations standards containing a mixture of analytes were prepared by 1% addition of each working solution in pooled blank K 3 EDTA plasma (e.g., at each concentration level, 10 µL of each of the two working solutions was added to 1 mL human plasma), to yield eight non-zero spiked calibration standards ranging from 0.100 to 74.626 ng/mL for SV and 0.100 to 48.971 ng/mL for SVA. Likewise, the lower limit of quantitation QC (LLOQ QC) samples (0.101/0.101 ng/mL) and QC samples at three concentration levels, namely, low (0.254/0.260 ng/mL), medium (23.914/15.472 ng/mL) and high (59.786/38.680 ng/mL) for SV/SVA, respectively, were prepared independently in pooled blank K 3 EDTA plasma. A modified procedure toward stabilizing the analytes in the biological matrix was applied, wherein a 3% of plasma, from each spiked calibration standards, QC samples as well as clinical samples during sample collection, was replaced with the buffer solution (5% v/v, formic acid in water). A maximum of 5% dilution of the plasma matrix was allowed. If not used, the calibration standards and quality control samples were stored in aliquots at around −50°C until analysis.
An ISTD working solution containing SV-D6 and SVA-D6 at a concentration of 40.0/40.0 ng/mL for SV/SVA, respectively, was prepared by diluting the stock solution of each in methanol-water (50:50, v/v). All the above-mentioned working solutions were prepared and stored under low light conditions in an ice-cold water bath until use.
SPE procedure
Plasma samples frozen at −50°C were thawed on the day of extraction in an ice-cold water bath followed by vortexing to ensure homogeneity. An eppendorf pipette was used to aliquot 0.200 mL of spiked plasma samples into labeled polypropylene tubes. To each tube then added 0.050 mL of internal standard working solution (40.0/40.0 ng/mL for SV/SVA, respectively) with the use of multistepper and vortexed for ∼30 s. To each tube, 0.600 mL of 100 ± 1 mM ammonium acetate in water titrated to pH 4.5 ± 0.1 using glacial acetic acid was then added, and vortexed again for 30 s. The total sample was then loaded onto an Oasis ® HLB disposable extraction cartridge (30 mg, 1 cc), which were previously conditioned with 0.500 mL of methanol and then with 0.500 mL of water. After loading of the samples, the cartridges were washed twice with 1 mL of 20% methanol solution in water. Finally, analyte and ISTD were eluted with 1 mL of methanol. The extracted samples were then evaporated to dryness using a Zymark TurboVap LV evaporator (Caliper, Hopkinton, MA, USA) and reconstituted with 0.300 mL of reconstitution solution consisting of acetonitrile: 2 ± 0.05 mM ammonium acetate in water titrated to pH 4.5 ± 0.1 with glacial acetic acid (40:60, v/v). The reconstituted samples were transferred to autosampler glass vials. Then, 25 µL of the sample was injected into the LC-MS-MS system for analysis. The whole sample preparation process was carried out in an icecold water bath (excluding vortex mixing, SPE and drying) and under low light conditions, to avoid temperature and light-induced degradation of the analyte.
Interconversion
The interconversion between the SV and SVA was evaluated under different experimental conditions. The concentration for SVA and its lactone counterpart were kept at about 25.0 ng/mL for each in plasma, during the interconversion study.
Influence of plasma temperature
The impact of plasma temperature toward the stability of SV and SVA in plasma was evaluated. Two sets of plasma samples were prepared: set-1 contains SV and SVA, and set-2 contains SVA. Four replicates from each set were processed and analyzed after being kept at room temperature and in an ice-cold water bath for different times. The changing trends in SV and SVA peak area response caused by interconversion were plotted against time.
Influence of anticoagulants
The role of various anticoagulants like lithium heparin, citrate phosphate dextrose adenine (CPDA), sodium fluoride (NaF) and ethylene diamine tetraacetic acid tripotassium salt (K 3 EDTA) toward instability of SV in plasma was evaluated and their efficiency toward restricting the conversion of SV to SVA was compared. Plasma containing the anticoagulant was taken separately and spiked with SV and being kept on bench for ∼4 h that acts as stability samples. Comparison samples were prepared at the end of 4 h. Four replicates from each set were processed and analyzed as per the protocol summarized above.
Influence of plasma pH
Several different strengths of acidified buffer were assessed to restrict the interconversion between the acid and lactone form of analytes. The buffer solutions that were tested include 5% formic acid (FA) in water ( pH 2.0), 25% FA in water ( pH 1.2) and 1 N HCl in water ( pH 0.0). Spiked plasma samples were prepared, containing both SV and SVA. Spiked plasma samples were then treated with these buffer solutions separately and kept at room temperature for about 4 h, which act as stability samples. Comparison samples were prepared at the end of 4 h. Four replicates from each set were processed and analyzed as per the protocol summarized above.
The percent change in acid and/or lactone form of analyte was calculated as: % change = (s − c)/c × 100, in which s and c represent the average peak area response of the analytes obtained from stability and comparison samples (n = 4), respectively.
Method validation
A thorough and complete method validation was carried out in accordance with the bioanalytical method validation guidelines published by the US FDA (24) . Bioanalytical method validation was performed to evaluate selectivity, sensitivity, linearity, accuracy, precision, recovery, matrix effect and stability of analyte during both short-term sample processing and long-term storage.
Selectivity
The selectivity of the method was evaluated by analyzing blank human K 3 EDTA plasma samples from six individual matrix lots along with one lipemic and one hemolytic lot with and without metabolite, frequently used concomitant medications to investigate the potential interferences of endogenous compounds coeluting at their retention times of analytes and ISTDs in drug-free plasma. For selectivity with metabolite and concomitant medication drugs, drug-free plasma was fortified in a concentration equivalent to therapeutic or high-therapeutic concentration. The metabolite and concomitant medication drugs tested were SVA acyl β-D-glucuronide and ezetimibe, fenofibric acid, niacin, acetaminophen and acetylsalicyclic acid, respectively.
Linearity and sensitivity
The linearity of the method was determined by analysis of standard plots associated with an eight-point calibration curve from accepted three precision and accuracy batches.
The calibration curves were constructed at 0.100-74.626 ng/mL for SV and 0.100-48.971 ng/mL for SVA. The calibration curves were fitted using a weighted (1/x 2 ) least-squares linear regression method by measuring the peak-area ratio of the analyte to the ISTD. The correlation coefficient (r) >0.99 was desirable for all calibration curves. The lowest standard on the calibration curve was to be accepted as the lower limit of quantification (LLOQ), if the analyte response was at least five times more than that of drug-free (blank) extracted plasma. Concentrations of QC samples and study samples were calculated in accordance with the calibration curves. The acceptance criterion for each back-calculated standard concentration was ±15% deviation from the nominal value, except for the LLOQ, for which a deviation of ±20% was permitted.
Accuracy and precision
The precision and accuracy of the assay were determined by analysis of the QC samples. Intraday precision and accuracy were evaluated by analysis of six replicates of QC samples at four levels during a single analytical run. The interday precision and accuracy were evaluated by analyzing 18 replicates of the QC samples at each level through three precision and accuracy batches runs on 2 consecutive validation days. Accuracy is required to be within ±20% for limit of quantitation quality control (LOQQC) and ±15% for the other QC samples and precision should not exceed 20% for LOQQC and 15% for the other QC samples.
Relative recovery, absolute matrix effect and process efficiency The relative recovery, absolute matrix effect and process efficiency (% PE) were assessed as recommended by Matuszewski et al. (25) . Because this method involved a terminal drying step, unextracted samples were prepared by reconstituting the postextracted blank plasma samples with the same neat standard solutions containing the analyte and ISTDs. Three parameters were estimated for the analytes at low, medium and high QC levels. Relative recovery (RRE) was calculated by comparing the mean peak area response from the extracted QC samples (spiked before extraction) to that of unextracted samples (spiked after extraction) containing analytes and ISTDs at approximate concentration representing the final extracted concentration for the analytes in respective QC samples and ISTDs. The RRE of ISTDs was similarly estimated. The absolute matrix effect (AME) was assessed by comparing the mean area response of unextracted samples (spiked after extraction) with the mean area of neat standard solutions (n = 3), containing analytes and ISTDs at concentration representing the final extracted concentration for the analytes in respective QC samples and ISTDs. The overall process efficiency (% PE) was calculated as (AME × RRE)/100.
Matrix effect
The matrix effect was evaluated at two concentration levels (LOQQC and HQC) in four different blank plasma lots along with one hemolyzed and one lipemic plasma matrix lot. From each lot, samples at LOQQC and HQC levels were prepared (spiked before extraction) in duplicate and checked for the % accuracy and precision (% CV) against the standard curve. The impact of matrix is considered to be nullified if the accuracy is within ±15% and ±20% from the nominal concentrations of HQC and LOQQC, respectively, and precision is within ±15% for HQC and ±20% for LOQQC.
Dilution integrity
Dilution integrity was investigated to ensure that samples could be diluted with blank matrix without affecting the final concentration. The dilution integrity test was performed by preparing samples at a concentration approximately between 160 and 180% of ULOQ in the screened plasma and were then diluted to two and four times with blank plasma to bring the concentration within the calibration curve. The acceptance criteria for the diluted samples should be the same as those of QC samples in precision and accuracy batch.
Stability
The absolute stability testing of analytes in the biological matrix should mimic the expected conditions for the study samples during sample storage and processing and was thus investigated by analyzing replicates (n = 4) of QC samples. The stability in plasma was evaluated in terms of freeze-thaw stability, bench top stability, long-term stability and autosampler stability. Freeze-thaw stability was evaluated after three freeze (at around −50°C)-thaw (ice cold water bath) cycles. Bench top stability was assessed in an ice-cold water bath, and the long-term stability was evaluated at −50°C. The stability of autosampler samples was determined after reconstitution (autosampler stability at 5°C). To determine the percentage absolute stability of analytes, the stability assessments were made at the LQC and HQC level by comparing the stability samples against freshly prepared calibration standards processed along with freshly spiked replicates (n = 4) of QC samples that act as comparison samples. The working solutions and stock solutions of analytes and ISTDs were also evaluated for their stability in an ice-cold water bath for about 9 h and at temperature −20°C for 7 days, respectively.
Method application
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover design was used for the assessment of pharmacokinetics and bioequivalence. Fourteen healthy, adult (age range 18-45 years), Indian male volunteers (having body mass index between 18.5 and 30.0 kg/m 2 ) who gave written informed consent took part in this study. The study was approved by Ethics Committee of Institutional Review Board at Majeedia Hospital (New Delhi, India). After an overnight fast of at least 10 h, all subjects were given a single oral dose of SV 40 mg tablet of Ranbaxy Pharsight Corp., Mountain View, CA, USA). The peak plasma concentration (C max ) and time to reach C max (T max ) were read directly from the experimental data. The total area under the plasma concentration-time curve from time zero to infinity (AUC 0−∞ ) and from time zero to the last measurable concentration (AUC 0−t ) were calculated using the trapezoidal rule-extrapolation method.
Incurred sample reanalysis
Incurred sample reanalysis (ISR) was performed on 98 sample points selected randomly from the study population. The basic objective of ISR was to reconfirm the initial values and to demonstrate that the assay is reproducible. The conformity of the original result with the ISR sample is calculated as a % difference. The % difference should be within 20% for at least 67% or two-third of the total reanalyzed subject plasma samples (26) , [% difference = absolute (reanalyzed value − original value)/average of reanalyzed and original value × 100%].
Results
Method development
Mass spectrometry optimization During the early stage of method development, both ESI and atmospheric pressure chemical ionization (APCI) sources were investigated. ESI offered much higher signal intensities for target analytes than APCI and was thus chosen as an ionization source. The ionization efficiency of SV and SVA was quite different. SV contain methoxy carbonyl groups, which can accept protons, be charged and display responses in (+)ESI mode. However, SV lack the functional group that could release protons, thus possessing no signal in (−)ESI mode. SVA contains the methoxy carbonyl group that can receive protons and aliphatic carboxylic and hydroxyl groups that can release protons. Hence, SVA shows responses in both (+)ESI or (−)ESI mode. Nevertheless, SVA displays higher signal intensities in (−)ESI mode than in (+)ESI mode because of its readiness to lose protons from the carboxylic group. In this context, negative-positive ionization switching was chosen, with SVA being monitored in (−)ESI mode and SV being acquired in (+)ESI mode. + was seen as a major peak, our efforts did not produce the anticipated signal intensity (14) (15) (16) (19) (20) (21) . Hence, in this context the ammonium-adducted ions [M+NH 4 ] + for SV and SV-D6 were employed to achieve the desired sensitivity. The ammonium content was from the ammonium acetate buffer used in the mobile phase and reconstitution solution. To reduce the occurrence of sodiumand/or potassium-adducted ions and to favor the formation of ammonium-adducted ions; first, the LC-MS grade organic buffer as well as solvents were utilized throughout the sample preparation and/or analysis. Second, the organic solvent containing alcohol such as methanol was avoided in the mobile phase and reconstitution solution. Figure 1 shows the product ion spectra of the analytes and their deuterated ISTDs and also displays their tentative fragmentation profiles. The product ion is formed by the loss of 3,2-dimethyl-butyrate moiety of the molecules. Deuterated ISTDs shared similar fragmentation patterns with their nonlabeled counterparts.
Liquid chromatography conditions
To select the starting conditions toward optimizing the LC parameters, we have paid attention to previous work (18) (19) (20) (21) , relating to the estimation of SV and SV along with its metabolite. In most of these studies, widely accepted C18 based analytical columns were employed to achieve good resolution with satisfying peak shape and peak symmetry. In this study, Ascentis ® Express C18 (75 × 4.60 mm, 2.7 µm) was chosen as an analytical column over the conventional C18 columns because it offers a really high-separation power with modest operating pressure. This technology of Fused-core ® particles, also called as small superficially porous particles, gained wider popularity toward improving separation efficiencies and speed without reducing particle size (27) . The optimization procedure was focused on the mobile phase composition as well as its pH, column oven temperature and injection volume. First, referring to the published work (15) (16) (17) (18) (19) , mobile phases composed of ammonium acetate buffer titrated to pH 4.5 and acetonitrile in different ratios were tested. The analytes exhibited satisfactory sensitivity, and the desired separation achieved between SV and SVA; however, matrix peaks affected the determination of SVA and showed ion-suppression for SVA. Resolution of the matrix peak from the SVA retention time was easily accomplished, when the aqueous content in the mobile phase consists of ammonium acetate buffer that was titrated to pH 4.0 and/or <4.0; unfortunately, this leads to a slight increase in total analytical run time (>1.0 min) but significantly reduce ion suppression encountered for SVA. Following subsequent optimization, it was possible to obtain the desired resolution and sensitivity with the mobile phase composed of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 3.8 with glacial acetic acidacetonitrile (25:75, v/v).
Simultaneously, tests were carried out to study the influence of the column temperature (between 25 and 55°C, at an increment of 5°C) on retention time and injection volume (from 10 to 50 µL) toward enhancing the sensitivity of the method. The best results were achieved when 25 µL was injected, and the column oven was maintained at 35°C. The set of samples prepared in reconstitution solution composed of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 4.5 with glacial acetic acid-acetonitrile (60:40, v/v) shows the symmetric peak shape and produces a higher signal-noise ratio (S/N) compared with those prepared in the mobile phase.
Under the chromatographic conditions described above, the D6-ISTDs were eluted at the same retention time as their corresponding unlabeled analytes. The retention times were 3.30 and 5.20 min for SVA and SV, respectively (Figure 2 ).
Sample preparation
During method development, different options were evaluated to optimize sample clean-up so as to eliminate possible matrix interferences, concentrate the sample and obtain a sample as clean as possible to preserve the life of the analytical column. Moreover, for the multicomponent analysis with significant differences in polarity, liquidliquid extraction and protein precipitation extraction could hardly guarantee good recovery. Thus, SPE was employed that always results in significant lower lipid levels, a significant source of matrix, compared with PPT and often produces excellent recoveries for polar and nonpolar analytes. Taking this into account, we employed an Oasis HLB SPE disposable cartridge to extract analytes from plasma samples. Use of 100 ± 1.0 mM ammonium acetate buffer titrated to pH 4.5 ± 0.05 during the sample preparation helps in breaking the drug-protein binding alongside stabilizing the analytes in the biological matrix. Additionally, 20% methanol in water during the washing step helps to remove polar matrix interferences from the cartridge bed. The extraction procedure described here offers a rapid way to isolate analytes and ISTDs from plasma matrix and provides scope for automation. Interconversion Figure 3 characterizes the interconversion profiles of the two analytes. In these plots, the tendency of the interconversion of the two analytes is observed evidently. The influence of temperature on stability of the SV and its acid counterpart was evaluated in plasma. The set-1 samples shows a prominent degradation of SV, and about 45 and 30% of SV degraded and mainly got converted to SVA in first 4 h, when kept at room temperature and in an ice-cold water bath, respectively ( Figure 3A) . In contrast, set-2 samples containing SVA found stable under both conditions demonstrated by an unchanged peak area response ( Figure 3B) . The influence of different anticoagulants on the interconversion was evaluated, and it was observed that anticoagulants like EDTA or NaF act as good inhibitors of ester hydrolysis and restrict the conversion of SV to its acid counterpart certainly to a good extent compared with other tested anticoagulants ( Figure 3C ). Simultaneously, the influence of different strengths of acidified buffer on the interconversion was investigated and shows that the addition of different acidified buffers to plasma could significantly affect the interconversion ( Figure 3D ). When plasma pH was not controlled, i.e., at normal plasma pH the SV would easily get converted to SVA. However, if plasma pH was made too acidic a decrease in peak area response for SVA observed; reasonably the SVA would have got cyclized to SV. The result obtained therein validates that an immediate addition of 3% buffer solution (5% v/v, FA in water) during sample collection in a clinic as well as CC standard and QC sample preparation in lab restricts the interconversion efficiently.
Method validation
Selectivity Figure 2 shows the typical MRM chromatograms of blank human plasma; plasma spiked only with ISTDs; plasma spiked with SV and SVA at LLOQ (0.100 ng/mL for each analyte) and ISTDs and a plasma spiked with SV and SVA at ULOQ (74.626 ng/mL for SV and 48.971 ng/mL for SVA) and ISTDs. Interfering peaks from endogenous components were not observed at the retention times of both the analytes and ISTDs. Furthermore, none of the studied concomitant medication and metabolite showed interfering signals at the retention time of analytes and ISTDs.
Linearity and sensitivity
The linear regressions of the peak area ratios versus concentrations were fitted over the range of 0.100-74.626 ng/mL for SV and 0.100-48.971 ng/mL for SVA in human plasma. The typical equations of the calibration curves were as follows: The LLOQ for this method was 0.100 ng/mL for each analyte. This level was sufficient for the clinical pharmacokinetic study of SV and its metabolite SVA following a single oral administration of SV. The sensitivity of the method was established using LOQQC samples analyzed in three consecutive validation runs. The intra-and interday precision and accuracy data for the LOQQC of the analytes are shown in Table II . The precision and accuracy values obtained were 
Precision and accuracy
Eighteen replicates of the QC samples from three consecutive validation runs were used to evaluate precision and accuracy at each concentration level. The intra-and interday precision and accuracy values of the QC samples are summarized in Table II . The intraday precision for both analytes was <4.2%, the interday precision was less than 7.3%
and the intra-and interday accuracy were between −2.7 and 7.9%. The intra-and interday precision and accuracy values were within the acceptable range. The method was thus judged to be accurate and reproducible.
Relative recovery, absolute matrix effect and PE The relative recovery, absolute matrix effect and PE data at LQC, MQC and HQC levels are presented in Table III . The precision (% CV) of relative recovery across the low, middle and high QC levels was <7.0%. The recovery for SV-D6 and SVA-D6 at the concentration employed was 77.9 and 75.3%, respectively. The result indicates that the extraction efficiency for analytes and ISTDs using SPE was satisfactory, consistent and was not concentration dependent.
Matrix effect
The extent of matrix effect in different lots of plasma (spiked before extraction) was well within the acceptable limit as evident from the precision (% CV) and accuracy values in Table IV . Results obtained therein indicate that no additional variations in plasma concentration due to the use of different plasma lots were observed.
Dilution integrity
The dilution integrity experiment was performed with an aim to validate the dilution test carried out on higher analyte concentration above the ULOQ, which may be encountered during real subject sample analysis. For SV and SVA, the precision for dilution integrity of ½ and ¼ dilution were <7.5% while the accuracy results were between −5.7 and 3.5, which is within the acceptance limit of 15% for precision (% CV) and 85-115% for accuracy.
Stability
The results of stability tests for the spiked plasma and extracts are shown in Table V . On the basis of the data, the analytes were stable during bench top storage for at least 6.63 h in an ice-cold water bath, for at least 77 h in the final extract under autosampler storage conditions, during three freeze-thaw cycles (−50°C to an ice-cold water bath), and in plasma placed at −50°C for 113 days. The stock solutions of analytes and ISTDs were found stable at −20°C for 7 days, and the working solutions of analytes and ISTDs were found stable for about 9 h in the ice-cold water bath.
Method application
Fourteen healthy Indian male subjects, 28.1 (5.84) years; 61.5 (6.62) kg body weight, 22.2 (2.19) kg/m 2 body mass index (mean with SD) participated in the pharmacokinetic study. All participated subjects completed both periods of the study. The mean concentration-time profile of SV and SVA in these volunteers is shown in Figure 4 , and the mean estimated pharmacokinetic parameters derived from the plasma concentration profiles are summarized in Table VI . The pharmacokinetic parameters almost overlapped between the test and reference samples. The C max and AUC values obtained in the present work were higher compared with the published reports (18, 20) . This variation can be attributed to the genetic difference, gender type (body size and muscle mass), food habits, etc. However, T max , T 1/2 and K el values were in good agreement with the work of Patel et al. (20) . The results of ISR, showing that 97.9 and 97.0% of sample points for SV and SVA, respectively, were within ±20% of the initial concentration value, further proving that the proposed method is reproducible and suitable for pharmacokinetic evaluation of SV.
Discussion
A sensitive, high-throughput and stability indicating LC-MS-MS method for the quantification of SV and SVA in plasma was developed and validated according to the USFDA guidelines. The use of 2.00 ± 0.05 mM ammonium acetate buffer titrated to pH 3.8 ± 0.1 as aqueous content of the mobile phase resolves interfering matrix peaks from RT of SVA and nullifies the ion suppression encountered for SVA. Most of the reported methods (Table I) emphasized toward restricting the interconversion that was occurring through stages of sample preparation and/or sample extraction stages until detection by maintaining sample pH acidic and/or lowering sample temperature to about 4°C. Unfortunately, these measures could not solve the instability problem completely. The interconversion between SV and SVA in plasma as well as factors influencing the interconversion was evaluated. The studies indicate that SV undergoes rapid degradation in plasma. Addition of a buffer solution (5% v/v, formic acid in water) to spiked calibration standards, QC samples as well as clinical samples during sample collection prevents the interconversion between SV and SVA completely.
Conclusion
We developed and validated a negative-positive ionization switching LC-MS-MS method for simultaneous determination of SV and SVA in plasma. Utilization of deuterated ISTDs guaranteed the success of the assay by eliminating the impact of matrix effect. This simple method completely resolved the instability problem of SV and SVA in plasma and was proved applicable to a pharmacokinetic study, thus providing efficient and robust support for further clinical studies.
